SCHEMBL876924

SCHEMBL876924

Cc1cc(-c2ccccc2)nc2cc(-c3nc([C@H]4CC[C@H](CO)CC4)n4ccnc(N)c34)ccc12.Cc1ccc(S(=O)(=O)O)c(C)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 5/20 0.54
IGF1R P08069 15/20 0.53
CYP3A4 P08684 4/20 0.53
INSR P06213 2/20 0.48
KDR P35968 2/20 0.48
RIPK2 O43353 1/20 0.48
ROCK2 O75116 1/20 0.48
LATS1 O95835 1/20 0.48
LCK P06239 1/20 0.48
LYN P07948 1/20 0.48
RET P07949 1/20 0.48
ABCB1 P08183 1/20 0.48
MET P08581 1/20 0.48
FGFR1 P11362 1/20 0.48
INSRR P14616 1/20 0.48
FECH P22830 1/20 0.48
MAPK3 P27361 1/20 0.48
MARK3 P27448 1/20 0.48
MAPK1 P28482 1/20 0.48
FLT4 P35916 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL401017 0.90 IGF1R (0.64) TNK2IGF1RCYP3A4INSRKDR
SCHEMBL401019 0.90 IGF1R (0.64) TNK2IGF1RCYP3A4INSRKDR
SCHEMBL4070293 0.86 IGF1R (0.51) TNK2IGF1RCYP3A4INSRKDR
SCHEMBL10226054 0.84 IGF1R (0.65) TNK2IGF1RCYP3A4INSRKDR
SCHEMBL399955 0.84 IGF1R (0.65) TNK2IGF1RCYP3A4INSRKDR
SCHEMBL10225411 0.83 IGF1R (0.55) TNK2IGF1RCYP3A4INSRKDR
SCHEMBL401929 0.82 IGF1R (0.77) TNK2IGF1RCYP3A4
SCHEMBL19264158 0.82 IGF1R (0.60) TNK2IGF1RCYP3A4INSRKDR
SCHEMBL401268 0.82 IGF1R (0.71) TNK2IGF1RCYP3A4INSRKDR
SCHEMBL13812432 0.82 TNK2 (0.65) TNK2IGF1RCYP3A4INSRKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653268-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2014-02-18 US disclosed
US-20130190496-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI Pharmaceuticals, LLC 2013-07-25 US disclosed
US-8367826-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2013-02-05 US disclosed
US-20120077979-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI Pharmaceuticals, LLC 2012-03-29 US disclosed
US-7820662-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2010-10-26 US disclosed
EP-1740591-B1 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS OSI PHARM INC (US) 2009-06-17 EP disclosed
US-20090118499-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077979-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 TNK2 405/4885IGF1R 1/4885CYP3A4 1815/4885
US-20130190496-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 TNK2 405/4885IGF1R 1/4885CYP3A4 1815/4885
US-20090118499-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 TNK2 405/4885IGF1R 1/4885CYP3A4 1815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.